Astec Lifesciences Ltd.

ASTEC

₹705.1

1.21% (8.4)

Market Cap

₹1,383 Cr.

P/E

0.00

About

Astec Lifesciences Limited, founded in 1994, specializes in manufacturing agrochemicals and pharmaceutical intermediates. With over 25 years of experience, the company has established strong global pa… Read more

Astec Lifesciences Limited, founded in 1994, specializes in manufacturing agrochemicals and ph… Read more

Low

648

52W Range

High

1474

Timeline

Key company specific updates

Company Timeline

Custom financial statementNew

Edit rows

In Rs. Cr.	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Sep 2024

In Rs. Cr.	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Sep 2024
Balance sheet
Net Block	94.67	103	115	167	194	213	340	318	386	490
Shareholders Funds	118	138	170	202	247	309	396	419	369	291
Profit & Loss
Operating Profit	31.56	62.40	68.80	76.47	85.18	111	154	76.25	-5.91	—
Net Sales	247	299	368	431	523	555	677	628	458	—
Cash flow
Cash from Operating Activity	-12.53	19.23	64.67	15.29	168	-8.16	23.60	74.66	10.22	11.89
Net Capex (est)	26.04	20.50	49.70	52.76	45.14	103	104	116	135	53.54
Ratios
ROCE (%)	22.78	36.88	35.60	32.17	29.19	26.41	29.94	12.28	-6.32	—
ROE (%)	4.21	13.85	20.57	17.65	19.27	21.04	22.66	6.10	-12.71	—

Forensics

5 Yes

Positive for this company

3 Neutral

Neutral for this company

8 No

Negative for this company

1 No Data

Insufficient data to analyse

Accounting & Shareholding

Depreciation Effect

Depreciation accounting is not leading to increase in profits
Pledge

Promoters have not pledged a significant portion of their holding
Retail Holding

Retail has been selling the stock which is usually a good time to buy
Promoter Holding

Promoter has not sold any shares in the last 90 days
Contingent Liabilities

Company has significant contigent liabilities which can be risky
Other Income

Other income component is making ratios of the company look optically better
Revenue Recognition

Chances of aggressive revenue recognition - operating profit of company is not getting converted to cash and recievables rising faster than sales

Price & Performance

ROE

Asset turnover is responsible for roe increase over last 10 years
Share price

Share price has increased over last 10 years due to earnings
Capex vs ROCE

Company has made significant capex which might be affecting its roce
Balance Sheet Strength

Balance sheet of the company is moderately strong
Debt

Company might have issues servicing its debt
Working Capital

Company has significant working capital which is dragging its roce and roe
Sales Growth

Sales of the company has grown at a slow pace
Margin Stability

Margins of the company are volatile
ROCE Strength

Roce of the company is not consistently strong
Current vs Historic Valuation

Unable to calculate due to limited data

Revenue mix

Product Wise Break-Up

Segment Break-Up

Location Wise Break-Up

Operational Metrics

R&D as a % of Total Sales (%)

Astec Lifesciences Ltd.

R&D as a % of Total Sales (%)
Source

Peer Comparison

Peer Name	Latest Price	PE	Market cap(Cr)	Prom Holding(%)	YoY Qtly Sales(%)	ROCE (%)	ROE (%)
Astec Lifesciences	705.1	0.00	1,383	66.75	84.78	-6.32	-12.71
Excel Industries	1,044.6	16.4	1,305	52.57	8.95	1.66	1.19
India Pesticides	131.1	24.19	1,512	63.61	14.3	10.2	7.29
Punjab Chem. & Corp	1,003.85	35.92	1,232	39.22	-0.13	22.49	16.23
Meghmani Organics	67.23	0.00	1,708	49.41	61.62	-3.6	-6.94
The Yamuna Syndicate	33,800	8.15	1,039	74.87	3.22	1.5	10.48
Insecticides India	625.7	13.38	1,815	72.3	-0.07	13.08	10.1
Heranba Industries	233.74	21.42	947	74.94	13.89	7.42	4.14

Corporate Actions

Consolidated Dividend

DATE

DETAILS

2023, Jul 21